NCT00774735View on ClinicalTrials.gov

GSK1349572 Drug Interaction Study With Protease Inhibitors

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Healthy SubjectsInfection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1349572

30 mg given in combination with lopinavir/ritonavir

DRUG

GSK1349572

30 mg in combination with darunavir/ritonavir

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

All Listed Sponsors

collaborator

Shionogi

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY